We excluded 17 RCTs (S1 File) for the following reasons: the dose used in the RCTs did not meet our criteria, open label extension with optional cross-over of placebo, included patients with kidney disease, was not double blind or assessed the combination of SGLT2-i and OAD or insulin. Here, SLC5A2 is linked to kidney disorder.